ReviewFrontiers in pharmacology2026
Therapeutic advances in eculizumab for atypical hemolytic uremic syndrome: a narrative review.
Review in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Atypical hemolytic uremic syndrome (aHUS) represents an uncommon, life-threatening complement-mediated thrombotic microangiopathy that is linked to both significant renal and extrarenal complications. Eculizumab, a monoclonal antibody targeting complement component C5, has dramatically improved patient outcomes and is widely recognized as a first-line therapy. However, uncertainty remains regarding the optimal dosing regimen, therapeutic monitoring, feasibility of treatment discontinuation, and appropriate duration of therapy in patients with aHUS. This narrative review is based on a PubMed literature search conducted through 2025, with search terms encompassing aHUS, eculizumab, complement inhibitor, treatment discontinuation, and dosing strategies. By integrating evidence from key clinical trials, observational cohorts, and registry-based analyses, a comprehensive evaluation of eculizumab's efficacy and safety profiles is presented. We discuss individualized management strategies, with particular emphasis on dose optimization. Importantly, we focus on the available evidence regarding eculizumab discontinuation, addressing its feasibility, relapse risk, and post-discontinuation monitoring strategies, and suggest that cautious treatment withdrawal can be considered in selected patients under close surveillance. In addition, tailored management approaches for specific aHUS subtypes are discussed. In conclusion, we outline future directions for complement C5 inhibition, emphasizing that the advancement and clinical implementation of novel C5 inhibitors may offer new opportunities for the long-term management of aHUS.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.